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Abstract 
 
 Cigarette smoking has become a worldwide problem leading to millions of fatalities 
every year. Although most smokers wish to quit, the current smoking cessation methods seem to 
be ineffective. In order to better understand the addictive qualities of cigarettes, researchers are 
starting to unravel the neurobiology behind nicotine dependence. The present study evaluated the 
role of glutamate in nicotine sensitization by measuring both locomotor and brain activities in 
nicotine-sensitized rats given the novel Group II metabotropic glutamate receptor antagonist 
LY341495. Subjects treated with LY341495 were expected to show a rise in locomotor activity 
since the drug was predicted to facilitate glutamate transmission, which would augment the 
effects of nicotine. However, results show that rats treated with the drug did not show a rise in 
locomotor activity. In addition, brain activity was expected to be seen in regions associated with 
the reward pathway (nucleus accumbens, amygdala, ventral tegmental area) and the basal ganglia 
after administration of LY341495. Results from fMRI appeared to show slight activation in the 
nucleus accumbens and amygdala but no apparent activity in the ventral tegmental area or basal 
ganglia. Furthermore, LY341495-treated rats appeared to have decreased brain activity compared 
to controls which, contrary to the initial hypothesis, could possibly be attributed to the drug’s 
ability to block the effects of nicotine. Thus, to better understand the effects of glutamate and 
LY341495, the present study should be repeated with an increased dosage of the drug and a 
greater sample size for imaging.   
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Introduction 
 
 
According to the American Heart Association, there are 24.8 million men (23.1%) and 
21.1 million women (18.3%) smokers in the United States alone. Cigarette smoking has become 
a worldwide problem and is now the main preventable cause of death. Tobacco use can lead to 
fatalities resulting from cancer, heart disease, stroke, and lung disease. In fact, smoking causes 
approximately 443,000 deaths annually in the United States alone and more than 5 million deaths 
worldwide. Although about 70% of smokers wish to quit, the current cessation methods are 
ineffective. Those who try to quit often experience depression-like symptoms as well as anxiety, 
cravings, irritability, mild cognitive impairments, and even physical ailments (CDC Fact Sheet, 
2011). These negative withdrawal symptoms are what often cause individuals to relapse, with 
rates as high as 80% in the first year. Although there are over 4,000 chemicals in cigarettes with 
51 of them carcinogenic, nicotine is the main ingredient responsible for addiction (Markou, 
2007). In order to fully understand the addictive qualities of cigarettes, researchers are now 
starting to unravel the neurobiology behind nicotine dependence.  
 
Effects of Nicotine on the Brain 
Acute administration of nicotine results in mild feelings of euphoria and slight cognitive 
enhancement in humans. These positive effects often lead smokers to continue with nicotine use. 
At this stage, the chronic nicotine state, neuroadaptations have occurred in response to persistent 
exposure to this psychostimulant (see Figure 2) (Markou, 2008). Similar to other drugs of abuse, 
nicotine is known to affect the mesocorticolimbic dopaminergic pathway, which is associated 
with the reward pathway in the brain (see Figure 1). This system consists of dopamine neurons 
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from the ventral tegmental area (VTA) projecting to the nucleus accumbens (NAcc), amygdala, 
and prefrontal cortex. The activity of dopamine neurons in the VTA is regulated by 
glutamatergic projections from the prefrontal cortex, cholinergic inputs from brainstem nuclei, as 
well as inhibitory inputs from GABA neurons in the VTA and nucleus accumbens (Xi et al, 
2009). 
When nicotine enters the brain, it has two main routes of action: 1) nicotine can bind to 
the nicotinic acetylcholine receptors (nAChRs) of the α4β2 subtype (higher affinity) on 
dopaminergic neurons to directly stimulate the release of dopamine into the nucleus accumbens 
or 2) it can bind to the nAChRs of the α7 subtype (lower affinity) on glutamatergic neurons to 
trigger the release of glutamate (see Figure 1). This neurotransmitter then interacts with the 
glutamate receptors on the postsynaptic dopamine neuron, opening the ion-gated channels of the 
ionotropic glutamate receptors, which induces firing and results in the release of more dopamine 
into the nucleus accumbens. Aside from stimulating the release of glutamate and dopamine, 
nicotine also binds to the nAChRs on GABAergic neurons to stimulate the release of GABA, the 
main inhibitory neurotransmitter in the brain (Markou, 2008). Since GABAergic neurons in the 
nucleus accumbens have dopamine receptors on the surface, firing of dopaminergic neurons in 
the VTA to the nucleus accumbens will result in dopamine binding to the GABAergic neurons, 
which would then cause the release of GABA back to the VTA dopaminergic neurons (Xi et al, 
2009).  
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Figure 1: Nicotine’s Effects on the Brain 
Nicotine has two main routes of action in the brain: 1) binding to α4β2 nAChRs on DAergic 
neurons in brain sites such as the VTA to directly stimulate release of DA into the NAcc or 2) 
binding to the α7 nAChRs on glutamatergic neurons to trigger the release of glutamate which 
then causes increased firing of the DAergic neuron and release of more DA into the NAcc (Xi et 
al, 2009). The small rectangles represent various receptors (D1-D3 represent DA receptors), 
bolded arrows show the directional transmission of the respective neurotransmitter, large ovals 
symbolize GABAergic or DAergic neurons, and the triangle represents a glutamatergic neuron.  
   
 
Nicotinic Acetylcholine Receptors  
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found in 
various parts of the body. Neuronal nAChRs consist of five subunits combined with a 
stoichiometry of two α- and three β-, or five α7-subunits. Found on presynaptic terminals as well 
as on postsynaptic cells, nAChRs of both α4β2 and α7 subtypes are the most prominent in the 
brain. As mentioned in the previous section, when nicotine binds to the excitatory nAChRs on 
presynaptic glutamatergic terminals, it causes an increase in glutamate transmission which then 
also results in an increase in dopamine transmission – partly due to the activation of postsynaptic 
nAChRs which causes an influx of Ca
++
 and increased excitability of the cell (Xi et al, 2009). 
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However, in the absence of nicotine, acetylcholine is the endogenous neurotransmitter 
that binds to and activates the nAChRs (see Figure 2a). Studies have shown that nAChRs of the 
α4β2 subtype have a high affinity for nicotine and thus, are critical mediators of nicotine’s 
rewarding effects. In rats, nicotine self-administration was ceased when subjects were given the 
α4β2 receptor antagonist dihydro-β-erythroidine (DHβE) (Watkins et al, 1999). In addition, 
genetic deletion of α4 or β2 subtypes inhibited nicotine-generated increases in dopamine levels 
in the nucleus accumbens (Picciotto et al, 1998; Marubio et al 2003). Receptors of the α4β2 
subtype have also been shown to be present in the majority of nicotine’s binding sites in the adult 
brain: brain slice analysis of α4- or β2-subunit knockout mice were devoid of high-affinity 
nicotine binding, indicating that most binding sites for nicotine contain receptors of the α4β2 
subtype (Picciotto et al, 1998; Picciotto et al, 1995).   
Aside from receptors of the α4β2 subtype, research has revealed that nAChRs of the α7 
subtype also play a role in nicotine’s rewarding effects. Similar to the α4β2 nAChRs, α7-
containing receptors are believed to be found on dopamine neurons in the VTA as well. In fact, 
one study showed that midbrain neurons in β2-subunit knockout mice were still activated by 
nicotine through interactions with α7 nAChRs (Wooltorton et al, 2003). Despite the presence of 
both receptor subtypes in the VTA, differences in distribution do exist, with α4β2 subtypes found 
predominantly on GABAergic terminals – though receptors of this subtype are also located on 
dopaminergic neurons – while α7 subtypes are found mainly on glutamatergic terminals (see 
Figure 1) (Xi et al, 2009).  
Frequent and recurring administration of nicotine can lead to rapid desensitization of 
α4β2 nAChRs, which then results in upregulation and increased expression of this receptor type 
on the cell surface. Evidence suggests that this nicotine-induced phenomenon is due to a protein 
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kinase C (PKC)-dependent pathway which involves the phosphorylation of immature α4 subunits 
on serine residues, resulting in receptor maturation and assembly (Wecker et al, 2010). Due to 
the differences in degrees of desensitization and affinity, it has been suggested that nicotine first 
interacts with and desensitizes α4β2 nAChRs (high affinity), while the lower affinity and 
desensitization rate of α7 nAChRs, along with instigating the release of glutamate, will extend 
the activation time of dopamine neurons (Xi et al, 2009).  
Aside from nAChR upregulation, chronic exposure to nicotine can also result in 
behavioral sensitization: frequent and recurring administration of nicotine causes long-term 
enhancement of dopaminergic and behavioral activity to the point where re-exposure to nicotine 
(even after weeks and months) will cause stronger dopaminergic and behavioral responses than 
observed initially. Therefore, behavioral sensitization is a result of nicotine-induced nAChR 
upregulation followed by long-term potentiation of excitatory inputs to dopamine neurons 
(Vezina et al, 2007). Numerous studies have been conducted on the relationship between 
nicotine and the dopamine system, but attention now is being directed to the glutamate system. 
More specifically, metabotropic glutamate receptors (mGluR) are now seen as potential targets 
for smoking cessation therapies.  
 
Glutamate  
In the mammalian central nervous system, glutamate is the major excitatory 
neurotransmitter and a contributor to the effects of nicotine. Glutamatergic terminals can be 
found in areas such as the VTA, nucleus accumbens, prefrontal cortex, and hippocampus. 
Glutamatergic afferent projections to areas such as the VTA, nucleus accumbens, and other brain 
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sites that contain dopaminergic cells or terminals originate from regions such as the frontal 
cortex, amygdala, and hippocampus (Markou, 2007).  
Both ionotropic (iGlu) and metabotropic glutamate (mGlu) receptors regulate the 
transmission of glutamate. Ionotropic glutamate receptors are mainly located postsynaptically 
and include NMDA (N-methyl-D-aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate), and kainate receptor subtypes (Markou, 2007). When activated, these 
receptors increase the cellular excitability by opening the glutamate-gated ion channels, allowing 
an influx of Na
+
 and Ca
++
 ions and outflow of K
+
 ions, which results in depolarization and firing 
of the postsynaptic cell (Xi et al, 2009).  
On the other hand, there are currently eight known mammalian subtypes of metabotropic 
glutamate receptors, and they have been classified into three groups (I, II, III) based on sequence 
homology, signal transduction pathways, and pharmacological selectivity. Metabotropic 
glutamate receptors are expressed in numerous areas throughout the brain and are slower acting 
compared to the ionotropic glutamate receptors. Group I receptors are mainly located 
postsynaptically and consist of mGlu1 and mGlu5 receptors. They couple to G-proteins to 
activate phospholipase C, and they also couple to intracellular Homer proteins that are vital for 
transporting mGlu receptors in and out of synapses. Depending on the situation, Group I 
receptors can be excitatory or inhibitory. Group II receptors are inhibitory autoreceptors found 
primarily presynaptically and consist of mGlu2 and mGlu3 receptors. They serve to negatively 
regulate the release of glutamate by presynaptic inhibition: glutamate released from the 
glutamatergic terminal binds to these inhibitory Group II receptors. Group II receptors couple to 
G-proteins to negatively regulate adenylyl cyclase activity – inhibiting the creation of the second 
messenger for signal transduction cAMP. Group III receptors are also mainly situated 
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presynaptically and consist of mGlu4, mGlu6, mGlu7, and mGlu8 receptors. They also couple to 
G-proteins but to decrease adenylyl cyclase activity (Markou, 2007).  
Since disruption in glutamate transmission has been linked to psychiatric disorders such 
as depression, anxiety, schizophrenia, and addiction, altering the activity of mGlu receptors has 
been suggested as a possible treatment for these illnesses (Chaki et al, 2003).  Given that mGlu 
receptors can be found throughout the brain, altering glutamate transmission in 
pharmacologically subtle ways would presumably affect motivated behavior without creating 
unwanted or even toxic side-effects (Conn and Pinn, 1997). In fact, a study conducted on an 
animal model of schizophrenia, known as the phencyclidine model, showed that the 
administration of an mGluII receptor agonist resulted in behavioral reversals such as improved 
working memory and locomotion. These behavioral improvements were seen despite continued 
dopamine hyperactivity in the subjects, providing evidence that dopamine does not have to be 
involved in treatments for psychiatric disorders (Moghaddam and Adams, 1998). 
The present study focused on Group II metabotropic glutamate (mGluII) receptors 
(mGlu2 and mGlu3). As mentioned earlier, the binding of nicotine to excitatory nAChRs on 
presynaptic glutamatergic terminals will cause an increase in glutamate transmission. As a result 
of the rise in levels of glutamate in the synapse, inhibitory mGluII receptors upregulate their 
activity to restore glutamate to pre-nicotine levels – signifying the chronic nicotine state. Thus, 
when smokers cease to smoke, glutamate transmission is decreased due to the increased activity 
of the inhibitory mGluII receptors (see Figure 2). This would then lead to a reduction in 
dopamine transmission which is often the cause for nicotine cravings and the associated negative 
withdrawal symptoms (Markou, 2007). 
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2a) Nicotine Naïve State 
 
 
 
 
 
 
   GLU       DA 
 
 
2b) Acute Nicotine State 
 
 
 
 
 
 
 
 
   GLU       DA 
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2c) Chronic Nicotine State 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   GLU       DA 
 
 
Figure 2: Nicotine’s Effects on Glutamate Transmission     
The triangle on the left represents the glutamatergic neuron and the oval on the right represents 
the postsynaptic DA neuron. The small rectangles symbolize acetylcholine, nicotine, or various 
presynaptic and postsynaptic receptors while the green ovals represent glutamate.   
2a) Acetylcholine is the endogenous neurotransmitter that binds to nAChRs in the absence of 
nicotine and causes glutamate to be released into the synapse. This neurotransmitter then binds to 
the postsynaptic glutamate receptors to increase cellular excitability, which results in firing of the 
postsynaptic DA neuron. 2b) Acute administration of nicotine results in an increase in glutamate 
transmission which then causes increased firing of the DA neuron and raised levels of DA in the 
NAcc. 2c) Since nicotine causes an increased release of glutamate, the inhibitory autoreceptors 
mGlu2 and mGlu3 (mGluII receptors) increase their activity to restore glutamate to pre-nicotine 
levels (shown in the figure as an increased number of mGlu2/3 receptors). This signifies the 
chronic nicotine state and dependence: nicotine is required in order for glutamate levels to be 
similar to that of the nicotine naïve state (Markou, 2007).     
 
The main subject of this study is the novel mGluII receptor antagonist LY341495. Since 
it is an antagonist, LY341495 is believed to increase glutamate transmission by binding to the 
mGluII receptors and preventing their inhibitory activity (see Figure 3). A previous study where 
no nicotine was involved showed that LY341495 had an antidepressant-like effect seen in the rat 
forced swim test and mouse tail suspension test (Chaki et al, 2003), with the idea that decreased 
glutamate transmission contributes to the depression-like state often experienced by smokers in 
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withdrawal. Moreover, LY341495 has also been proven to attenuate the reward deficits – 
elevations in self-stimulation thresholds measured via intracranial self-stimulation by rats in the 
chronic nicotine state – which is often associated with nicotine withdrawal (Kenny et al, 2003). 
 
 
 
 
 
 
 
 
 
 
   GLU       DA 
 
Figure 3: Administration of the mGluII receptor antagonist LY341495 is believed to increase 
glutamate transmission and restore glutamate to pre-nicotine levels by blocking the inhibitory 
effects of the mGluII receptors (Markou, 2007).  
 
 
The goal of the present study is to evaluate the role of glutamate in nicotine sensitization 
by observing the effects of LY341495 on locomotor and brain activity in nicotine-sensitized rats. 
In drug studies, neural sensitization occurs when the effects of a drug are increased after repeated 
administration, whereas tolerance occurs when the effects of a drug are decreased upon repeated 
administration. However, behavioral sensitization is the process in which the same dosage of 
drug is given, but the behavioral effects – locomotor activity – gradually increases before 
reaching a plateau. A model associating the interactions of dopamine, glutamate, and GABA has 
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been proposed to be involved in the induction and expression of behavioral sensitization (see 
Figure 4). 
 
     
Figure 4: Model of the interaction among Glu, GABA, and DA believed to be involved in the 
induction and expression of behavioral sensitization (Vanderschuren and Kalivas, 2000). The 
arrows show the direction of transmission for each respective neurotransmitter. PFCd = dorsal 
prefrontal cortex (prelimbic and anterior cingulate), PFCv = ventral prefrontal cortex 
(infralimbic), Nac = nucleus accumbens core, Nas = nucleus accumbens shell, BLA = basolateral 
amygdala, VTA = ventral tegmental area. The VTA and BLA send signals to both the Nac and 
Nas (DA and Glu, respectively).      
 
 
In nicotine naïve rats, the first few doses of nicotine will result in decreased locomotor 
activity. After repeated exposure to this psychostimulant, the rats will be in the chronic nicotine 
state (see Figure 2c). Behavioral sensitization to nicotine will also occur, marked by increased 
locomotor activity. This phenomenon is due to tolerance to nicotine’s depressant effects (Collins 
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et al, 1988) and sensitization to its stimulant effects (Clarke and Kumar, 1983a; Ksir et al, 1985) 
– which can be attributed to stimulation of dopamine neurons (Balfour et al, 1998).  
The effects of the mGluII receptor antagonist on locomotor activity of nicotine-sensitized 
rats were assessed by an open-field test which measured the total distance traveled by each 
subject. Research has shown that reducing glutamate transmission inhibits the rewarding effects 
of nicotine (Markou, 2008). Since LY341495 is thought to increase glutamate transmission, 
nicotine-sensitized rats treated with the drug are expected to show a rise in locomotor activity. 
Results from a separate study where no nicotine was involved show that mice that received 
subcutaneous injections of LY341495 displayed an increase in locomotor activity (O’Neill et al, 
2003).  
In order to observe the effects of LY341495 in the brain, functional magnetic resonance 
imaging (fMRI) was used to study localization of brain activity. This non-invasive procedure 
measures BOLD (blood-oxygenation-level-dependent) response: relative to the resting state, an 
increase in concentration of oxygenated blood indicates neural activity while an increase in 
deoxygenated blood indicates neural inactivity (Logothetis, 2002). Previous studies have shown 
that exposure to cigarette/nicotine-related cues to those dependent – which leads to craving – 
results in increased activity of the mesolimbic system (right posterior amygdala, posterior 
hippocampus, VTA, and medial thalamus) (Due et al, 2002) as well as increased glucose 
metabolism in parts of the anterior paralimbic system (anterior cingulate cortex (ACC), posterior 
orbitofrontal cortex (OFC), and anterior insula), dorsolateral prefrontal cortex (DLPFC) and right 
superior sensorimotor cortex (Brody et al, 2002). Hence, rats are expected to show positive 
BOLD response in brain regions associated with craving before nicotine administration.  
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After the injection of nicotine, rats that received the mGluII antagonist are expected to 
show positive BOLD signal changes in the rat reward pathway – specifically in the prefrontal 
cortex, VTA, nucleus accumbens, and amygdala – since the increase in glutamate transmission 
would presumably amplify the rewarding effects of nicotine. In addition, there is evidence that 
increased activity at glutamatergic projections from the prefrontal cortex to nucleus accumbens 
enhances cocaine seeking in rats (Moran et al, 2005), and the actions of nicotine appear to be 
very similar to this central nervous stimulant. Finally, activation of the basal ganglia (caudate 
nucleus, putamen, globus pallidus, subthalamic nucleus, and substantia nigra) is also expected. 
This brain region plays a vital role in the control of movement and is rich with mGluII receptors 
(Sacaan et al, 1992; Wright et al, 1994). 
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Materials and Methods 
 
Animals  
Male Sprague-Dawley rats (behavioral test n=16: LY341495-treated group n=8, 
control/saline-treated group n=8; imaging: LY341495-treated group n=2, control/saline-treated 
group n=4 ) (from Harlan Laboratories) weighing 300-350 g upon arrival in the laboratory were 
housed two per cage in a temperature- and humidity-controlled room on a 12 hour reverse light-
dark cycle (lights off at 9 AM). After arrival, rats were given approximately 5 days to become 
accustomed to their new environment before any testing. All open-field experiments and imaging 
were performed during the dark phase of the light-dark cycle. Food and water were readily 
available (except during testing). A different batch of rats was used in the imaging study (not the 
same subjects from the open-field test). All experimental procedures were in accordance with 
NIH guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) of 
the University of Massachusetts Medical School.  
 
Drugs 
(-)Nicotine hydrogen tartrate was purchased from Sigma (St. Louis, MO) and dissolved 
in saline, with pH adjusted to 7 with sodium hydroxide. Rats were given 0.4 mg/kg of nicotine 
immediately before being placed into the open arena. The novel mGluII receptor antagonist 
LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-[xanth-9-yl]propionic acid] 
was purchased from Tocris Bioscience Cookson (Ballwin, MO) and dissolved in saline, 
administered (1mg/kg) via subcutaneous injections in a volume of 1 mL/kg of body weight. 
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LY341495 was administered 30 minutes prior to the nicotine injection and before placement into 
the open-field arena. 
 
 
Open-field arena 
Rats were placed into a 90 cm x 90 cm black Plexiglas square box with an open top. Two 
red light bulbs and a video camera were mounted approximately 3 ft. above. The camera was 
connected to the video tracking software EthosVision to measure the rats’ locomotor activity: the 
program divided up the arena into squares and measured the amount of time that the rat stayed in 
each section.  
 
  
fMRI magnet 
A Bruker 4.7T/40cm horizontal magnet with a 20 Gauss/cm magnetic field gradient 
insert (inner diameter = 12cm, Bruker, Billerica, MA, USA) was used for the imaging studies. 
Rapid acquisition relaxation enhanced sequence (RARE) with TR (relaxation time) = 2 sec, TE 
(echo time) = 12 msec, resolution matrix = 256 x 256, FOV (field of view) = 30 mm x 30 mm, 
eighteen 1.2 mm slices were used to generate high resolution multi-slice anatomical images. 
With the same FOV and slice thickness at 1800 repitions, the saline/LY341495 and nicotine 
scans used echo-planar imaging sequence (EPI) at a resolution of 64 x 64. TR = 1 sec, TE = 30 
msec, and each scan ran for a total of 30 minutes. In the first EPI scan, a 1 minute baseline 
period was allotted before injection of saline (control) or LY341495 (treatment). Afterwards, a 
second EPI scan also totaling to 30 minutes was performed, with a 1 minute period reserved for 
baseline before injection of nicotine. Rats were secured into a dual coil restrainer (volume and 
surface coils) before being placed into the magnet. 
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Experimental procedures: 
 
Open-field test 
Behavioral studies were performed at the same time on all test days. After allowing the 
rats to become accustomed to their new environment for approximately 5 days, each rat was 
individually placed into the open arena and its locomotor activity was recorded for a 30 minute 
session to establish a baseline (Day 0) (see Figure 5). Each rat was given a subcutaneous mock 
injection 30 minutes prior to being placed into the arena to let them become accustomed to this 
procedure and reduce stress on the actual treatment days. For the next 5 consecutive days (Days 
1-5), each rat was given a mock injection followed by a subcutaneous  nicotine injection 30 
minutes later and immediately placed into the open arena for a recorded 30 minute session. On 
Days 6 and 7, the rats were divided into the test group (LY341495-treated) and control group 
(saline-treated). All procedures were the same as before but instead of a mock injection, rats 
were either given a SC injection of LY341495 or saline 30 minutes prior to nicotine and testing.     
 
Day  
0    OFT 
1    Nicotine    OFT  
2    Nicotine    OFT 
3    Nicotine    OFT  
4    Nicotine    OFT 
5    Nicotine    OFT 
6    Saline/LY341495   Nicotine  OFT 
7    Saline/LY341495   Nicotine  OFT  
 
Figure 5: Open-Field Test Experimental Procedures 
On Day 0 of the open-field test (OFT), no drugs were given and subjects were placed into the 
open arena in order to establish a baseline locomotor activity. For the next 5 consecutive days 
(Days 1-5), rats received daily SC injections of nicotine before being immediately placed into the 
arena. On Days 6 and 7, subjects received either saline (control group) or LY341495 (treatment 
group) 30 minutes prior to nicotine administration before being placed into the arena.   
 
21 
 
Imaging 
Aside from allowing the rats to familiarize themselves with their new environment for 5 
days, a validated acclimation procedure (King et al, 2005) was also performed in order to reduce 
stress for the animals while imaging. A Lidocaine (2.5%) and Prilocaine (2.5%) paste was 
applied to the ear canals of each rat 30 minutes prior to the acclimation procedure to numb the 
area and minimize discomfort. Each subject was first lightly anesthetized with isoflurane. 
Afterwards, a plastic semicircular headpiece with blunted ear supports to fit into the ear canals 
was placed on each rat’s head (on site of Lidocaine and Prilocaine paste application). The head 
of the rat was placed into a cylindrical head restraint and its incisors were secured over a bite bar. 
A screw on each side of the head restraint (total of 2) aligned up with the headpiece to secure the 
rat’s head. After being strapped into the head restraint, the animal’s body was placed into a 
custom-fitted cylindrical plastic tube with its limbs taped to reduce motion and prevent the 
subject from breaking free. Finally, an opaque tube was placed over the head restraint to imitate 
the darkness of the fMRI magnet. The rat in its body tube and head restraint covered by the 
opaque tube was then placed next to a speaker in a dark, isolated room playing a recording of the 
actual scanner noise. This procedure was conducted for 8 days with gradual increases in time 
exposed to the fMRI recording: 15, 30, 45, 60, 75, and 90 minute sessions (75 and 90 minute 
sessions were performed twice).         
Upon completion of the acclimation procedure (after 8 sessions), rats were given a daily 
subcutaneous injection of nicotine for 7 consecutive days (Days 1-7). Similar to the open-field 
test, subjects were also given either saline (control group) or LY341495 (treatment group) 30 
minutes prior to the nicotine injection on Days 6 and 7.      
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Rats were imaged on Day 7 and, similar to the acclimation procedure, they were given 
Lidocaine (2.5%) and Prilocaine (2.5%) paste 30 minutes prior to anesthesia with isoflurane. A 
semicircular headpiece was placed over the ear canals, and the rat’s head was secured into the 
head restraint. Since the rat cannot be given a subcutaneous injection while in the magnet, 2 
labeled syringes (1 with nicotine and the other with saline or LY341495), with wing needle 
extensions to allow for injections from outside the magnet, were placed into the rat’s back. The 
subject’s body was then placed into the imaging tube (dual coil restrainer) and into the fMRI 
magnet. Each rat underwent 3 scans that totaled to 108 minutes (see Figure 6): an 8 minute 
anatomy scan followed by two 30 minute EPI scans (saline or LY341495 and then nicotine). In 
both the saline (control) and LY341495 (treatment) EPI scans, saline and LY341495 were 
administered 1 minute after the beginning of the scan in order to establish a baseline for BOLD 
responses. After the 30 minute long saline or LY341495 scan, the second EPI scan was 
performed and nicotine was also administered to both the control and treatment groups after one 
minute in order to establish a baseline.   
  
          
Baseline      Saline or LY341495  Baseline Nicotine  
(1 minute)   (immediately after Baseline) (1 minute) (immediately after  
        Baseline) 
 
         l—l----------------------------------------------l—1------------------------------------l  
l-----------------------l--------------------------------------------------l----------------------------------------l       
Anatomy Scan       EPI Scan: Saline or LY341495    EPI Scan: Nicotine 
(8 minutes)        (30 minutes)      (30 minutes) 
 
Figure 6: fMRI scans 
Each rat underwent 3 scans that totaled to 108 minutes: 1) 8 min. anatomy scan, 2) 30 min. EPI 
scan where saline (control) or LY341495 (treatment) was injected after obtaining 1 min. 
baseline, and 3) another 30 min. EPI scan where nicotine was injected after obtaining 1 min. 
baseline. 
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Analysis: 
 
Open-field test 
Each subject’s total locomotor activity (total distance traveled) for all test days was recorded 
during the open-field test and calculated by EthosVision. Microsoft Excel was then used for 
statistical measurements: mean, standard deviation, ANOVA (between control and treatment 
groups as well as within the treatment group).  
 
 
fMRI 
Imaging results were extracted from ParaVision and imported into MIVA to line up brain slices 
from the anatomical scans of each rat to the standard anatomy/representative and then aligned 
with a segmented digital rat brain atlas. Afterwards, Matlab (Math-Works Inc., Natick, MA) was 
used to correct any motion artifact before the data from all rats in a group were averaged. SPM8 
(Statistical Parametric Mapping) was then used to generate the resulting BOLD response images. 
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Results 
 
Since LY341495 is a Group II metabotropic glutamate receptor antagonist, it is believed 
to block the inhibitory activity of mGluII receptors. As a result, more glutamate can be 
transmitted which then ultimately leads to increased dopamine transmission. Increasing 
dopamine transmission is hypothesized to augment the acute effects of nicotine. In the present 
study, an open-field test was used to measure the effects of LY341495 on locomotor activity in 
nicotine-sensitized rats. In addition to assessing behavioral changes, fMRI was also conducted to 
view differences in brain activity localization as a result of LY341495.   
 
Open-field test 
Since LY341495 is believed to increase glutamate transmission, nicotine-sensitized rats 
treated with the drug are expected to show an increase in locomotor activity. To test this 
hypothesis, an open-field test was used to measure the mean locomotor activity for both the 
control (receiving saline) and treatment groups (receiving LY341495). The experiment required 
a total of 8 days, where Day 0 represented the baseline (no LY341495, saline, or nicotine were 
administered). Afterwards, all subjects received a daily subcutaneous injection of nicotine (Days 
1-7), but on Days 6 and 7, the treatment group was also given LY341495 30 minutes prior to the 
nicotine injection, while the control group was given saline 30 minutes prior to nicotine (see 
Figure 5).  
The mean locomotor activity for both the control and treatment groups can be seen in 
Figure 7 (see raw data in Appendix). Day 0 represents the baseline – no nicotine, saline, or 
LY341495 was given. The mean locomotor activity for both the test group (n=8) and control 
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group (n=8) were very similar on Day 0. A major drop in locomotor activity was also seen in 
both groups on Day 1 – when all subjects were given their first dose of nicotine. From Day 1 
onwards, both groups showed a general increasing trend in mean locomotor activity. However, 
aside from Day 0, the control group always had higher average activity compared to the 
LY341495 group. In fact, significant differences in locomotor activity were seen between the 
groups on Days 6 and 7. On Days 6 and 7 where the subjects received either saline or LY341495, 
the control group seemed to reach a plateau while the test group still showed increase in 
locomotor activity – though not significant – but never reaches past 11,018.32 cm. Overall, the 
control group had higher mean locomotor activity that increased at a greater rate compared to the 
test group on all days except on baseline (Day 0) and treatment days (Days 6 and 7).   Although 
these results suggest a difference between treatment and control groups, they are difficult to 
interpret because the treatment group’s mean locomotor activity was consistently lower than the 
control’s mean activity (aside from baseline). Moreover, the differences in locomotor activity 
(within group) seen on Days 6 and 7 of the treatment group were not statistically significant 
(compared to each other and Day 5).   
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Figure 7: Mean Locomotor Activity from Open-Field Test  
The locomotor activity for the control (n=8) and LY341495-treated (n=8) groups were recorded 
on all days by EthosVision. The total distance moved (cm) by the subjects in each group were 
averaged and standard deviations were calculated (capped black lines). Subjects did not receive 
any nicotine, saline, or LY341495 on Day 0 (baseline), but they did receive nicotine on Days 1-
7. On Days 6 and 7, the control group received saline 30 minutes prior to the nicotine injection 
while the treatment group received LY341495 30 minutes before nicotine. ANOVA (p < 0.05) 
was performed between groups for Days 1-5 and within group for Days 5-7.   
 
 
 
fMRI 
After performing the open-field test to measure behavioral differences (locomotor 
activity), the effects of LY341495 in the brain of nicotine-sensitized rats were also assessed 
through fMRI. A new batch of rats were used (not the same subjects from the open-field test) but 
since the imaging study should mirror the behavioral study, the rats were again divided into the 
control and treatment groups. In order to reduce stress, which would affect the imaging results, 
all rats underwent an acclimation procedure prior to the imaging session (see Methods for 
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details). After acclimation, subjects were given a subcutaneous injection of nicotine for 7 
consecutive days, similar to the open-field test, and imaging was performed on Day 7. The rats 
received either LY341495 or saline 30 minutes prior to the nicotine injection on both Days 6 and 
7, but on Day 7, the drugs (LY341495 and nicotine) and saline were administered while the rat 
was in the magnet.   
 On the imaging day (Day 7), after being properly secured into the head restraint and body 
tube, the subjects were placed into the magnet for a 108 minute-long scan: an 8 minute anatomy 
scan and two 30 minute EPI scans (for saline or LY341495 and nicotine). Figures 8 and 9 show 
the imaging results from the two groups that were gathered through ParaVision and generated 
from Matlab. The threshold for the images is set at 1.0, which means that differences in blood-
oxygen-level below or above 1% are detected and shown. The orange/yellow represents positive 
BOLD response (increase in concentration of oxygenated blood, signifying neural activation) 
while the blue represents negative BOLD response (increase of deoxygenated blood, signifying 
neural inactivation).  
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8a) Control: Saline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8b) Control: Nicotine  
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Figure 8: BOLD Response from fMRI of Control Group (n=4) 
(DISCLAIMER: Images were obtained from a separate nicotine study that followed the same 
protocol as the present study except a different drug – an NMDA receptor antagonist CGP39551 
– was used. The control group received the same treatment and drugs as the control group in the 
present study.) After the initial anatomical scan, two 30 minute EPI scans were performed (after 
injection of saline and then after nicotine). The 16 images are brain slices from the forebrain to 
the hindbrain in numerical order. (MO = somatomotor area, SS = somatosensory area, ACC = 
anterior cingulate cortex, NAcc = nucleus accumbens, ILA = infralimbic area, RSP = 
retrosplenium, AMY = amygdala, VTA = ventral tegmental area)  
 
 
Figure 8a shows images of the control group in the nicotine-craving state after receiving 
saline. Previous studies have shown that exposure to cigarette/nicotine-related cues to those 
dependent – which leads to craving – results in increased activity of the mesolimbic system 
(right posterior amygdala, posterior hippocampus, VTA, and medial thalamus) (Due et al, 2002) 
as well as increased glucose metabolism in parts of the anterior paralimbic system (anterior 
cingulate cortex (ACC), posterior orbitofrontal cortex (OFC), and anterior insula), dorsolateral 
prefrontal cortex (DLPFC) and right superior sensorimotor cortex (Brody et al, 2002). Thus, the 
saline scan was expected to show increased BOLD activity in parts of the mesolimbic and 
anterior paralimibic systems as well as in the DLPFC and right superior sensorimotor cortex. 
Seen in images 9 and 10 of Figure 8a, there is activation in the somatomotor (MO) and 
somatosensory (SS) areas. However, there does not seem to be much activation in other expected 
areas (Figure 8a): amygdala (AMY) (image 11), VTA (image 14), and the ACC (image 8) – 
though other regions such as the hippocampus, thalamus, OFC, anterior insula, and DLPFC 
cannot be as clearly identified from the imaging results.  
After the 30 minute saline scan, rats received nicotine and underwent another 30 minute 
EPI scan. Since nicotine, similar to other drugs of abuse, is known to affect the 
mesocorticolimbic dopaminergic pathway, which is associated with the reward pathway in the 
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brain, positive BOLD activity was expected to be seen in the VTA, nucleus accumbens, 
amygdala, and prefrontal cortex (Xi et al, 2009). Figure 8b shows the imaging results after 
nicotine administration. Comparing Figures 8a and 8b, increased activation can be found in both 
the ACC and infralimbic area (ILA) seen in images 4-8, as well as a slight increase in activation 
of the retrosplenium (RSP) seen in images 9-10. However, there now seems to be decreased 
activation in the somatomotor and somatosensory areas (compare images 9 and 10 between 
Figures 8a and 8b). Furthermore, components of the reward pathway – the VTA (image 14 of 
Figure 8b), nucleus accumbens (image 5 of Figure 8b), and amygdala (image 11 of Figure 8b) – 
did not show much activation either after nicotine administration.  
Since nicotine sensitization results in increased locomotor activity in rats (Balfour et al, 
1998), positive BOLD responses were also speculated to be seen in components of the motor 
loop, more specifically, in the basal ganglia (caudate nucleus, putamen, globus pallidus, 
subthalamic nucleus, and substantia nigra). However, there does not seem to be much general 
activation of the basal ganglia – though specific components of this region cannot be as clearly 
identified from the imaging results. Overall, when comparing the saline scan to nicotine scan, 
aside from the already mentioned differences in brain activity, there does not appear to be a 
significant increase or decrease in BOLD response - though slight decreases in response can be 
seen in different brain areas in images 8, 10, and 14 of Figure 8b.  
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9a) Test Group: LY341495 
 
 
9b) Test Group: Nicotine 
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Figure 9: BOLD Response from LY341495-Treated Rats (n=2) 
After the initial anatomical scan, two 30 minute EPI scans were performed (after injection of 
LY341495 and then after nicotine). The 16 images are brain slices from the forebrain to the 
hindbrain in numerical order. (MO = somatomotor area, SS = somatosensory area, ACC = 
anterior cingulate cortex, NAcc = nucleus accumbens, ILA = infralimbic area, RSP = 
retrosplenium, AMY = amygdala, VTA = ventral tegmental area)  
 
 
 
  
The imaging procedure for the treatment group (receiving LY341495) was the same as 
that of the control group but LY341495 was administered instead of saline in the first EPI scan.  
Figure 9a shows images obtained after subjects received LY341495, and similar to the control 
group (Figure 8a), the rats were craving nicotine at this point. As a whole, the scans from the 
treatment group (Figure 9a) show more scattered positive BOLD responses compared to the 
scans from control group (Figure 8a), which show more concentrated positive BOLD responses.  
In addition, there are more negative BOLD responses in Figure 9a compared to Figure 8a – seen 
prominently in images 9-16. In contrast to the saline scan (Figure 8a), there does not seem to be 
significant activation of the somatomotor or somatosensory areas (image 9 of Figure 9a) in the 
LY341495 scan. However, there appears to be slight increased activation of the infralimbic area 
seen in image 6 (compare Figures 8a and 9a). Moreover, similar to the saline scan, there does not 
seem to be much activation in the other areas that are linked to nicotine craving (Figure 9a): 
amygdala (image 11), VTA (image 14), and the ACC (image 8) – other regions such as the 
hippocampus, thalamus, OFC, anterior insula, and DLPFC cannot be as clearly identified from 
the imaging results.   
Figure 9b shows the results of the nicotine scan for LY341495-treated subjects. 
Comparing the LY341495 (Figure 9a) and nicotine (Figure 9b) scans, there does not appear to be 
an overall increase in positive BOLD response – though there are slight increases in brain 
regions seen in images 1 and 2, 5 and 6 (increased response in the infralimbic area), as well as 11 
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(increased response in somatomotor and somatosensory areas). In fact, there seems to be a 
general decrease in BOLD response between Figures 9a and 9b, seen prominently in images 8-12 
and 15-16. However, there does appear to be slight activations in components of the reward 
pathway seen in the nucleus accumbens (image 5 of Figure 9b) and amygdala (image 11 of 
Figure 9b) but no apparent activation of the VTA (image 14 of Figure 9b). Similar to the nicotine 
scan for the control group, there does not seem to be activation in the basal ganglia – though 
specific components of this brain region cannot be as clearly identified from the imaging results. 
On the other hand, a decrease in BOLD response can be seen in the ACC, infralimbic area, and 
retrosplenium when comparing the treatment group (Figure 9b) with the control group (Figure 
8b) (images 5-10). These results suggest that there is decreased corticolimbic activity between 
the control and treatment groups, and the decrease in BOLD response seen in the treatment 
group’s nicotine scan (Figure 9b) may be attributable to the effects of LY341495. 
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Discussion 
 
Of the 51 known carcinogenic chemicals in cigarettes, nicotine is the main component 
that leads to addiction (Markou, 2007). Extensive studies have been performed on the 
relationship between nicotine and dopamine, but focus is now being turned to another 
neurotransmitter that works closely with the dopamine system – glutamate. When nicotine enters 
the brain, it can bind to nAChRs on dopaminergic neurons to directly stimulate the release of 
dopamine into the nucleus accumbens, or nicotine can bind to the nAChRs on glutamatergic 
neurons to trigger the release of glutamate, which then results in the release of more dopamine 
(see Figure 1) (Markou, 2008). The present study focused on the effects of blocking Group II 
metabotropic glutamate receptors in nicotine-sensitized rats with the use of the novel mGluII 
receptor antagonist LY341495.  
 
Open-field test 
The effects of LY341495 on locomotor activity were measured by an open-field test. 
Since LY341495 was believed to prevent the inhibitory activity of the mGluII receptors, an 
increase in glutamate transmission was predicted to occur, followed by a rise in dopamine 
transmission in nicotine-sensitized rats. An increase in the level of dopamine in the terminal 
regions of the mesolimbic system – which projects mainly from the VTA to the nucleus 
accumbens – is thought to be responsible for the psychomotor-stimulant effects of nicotine 
(Clarke et al, 1988; Louis and Clarke, 1998; Pontieri et al, 1996). However, the initial dose of 
nicotine is known to cause a decrease in locomotor activity in nicotine-naïve rats. After repeated 
doses, though, the subjects become sensitized to the effects of nicotine; that is, they develop 
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tolerance to its depressant effects (Collins et al, 1988) and sensitization to its stimulant effects 
(Clarke and Kumar, 1983a; Ksir et al, 1985).  As a result, their locomotor activity will increase, 
which is believed to be caused by the stimulation of dopamine neurons (Balfour et al, 1998). 
Since LY341495 is predicted to increase glutamate transmission by blocking the inhibitory 
effects of mGluII receptors and thus, augment the effects of nicotine, nicotine-sensitized rats 
treated with LY341495 in the present study were predicted to exhibit an increase in locomotor 
activity. However, results from the open-field test did not support this hypothesis.  
Seen in Figure 7, both the control and LY341495-treated groups showed the expected 
initial drop in locomotor activity from Day 0 (baseline) to Day 1. Both groups also exhibited a 
general gradual increase in mean locomotor activity from Days 1-7, but the control group had 
higher values for all those days – significantly higher on Days 6 and 7. While the control group 
seemed to have reached a plateau on Days 6 and 7 – when subjects were given either saline or 
LY341495 – the treatment group still exhibited a gradual increase in mean locomotor activity. 
Though the slight increases followed the overall increasing trend established from the previous 
days, LY341495 did not appear to have a significant effect on locomotor activity. The difference 
in activity between Day 5 and 6 was only approximately 260 cm and the difference between Day 
6 and 7 was approximately 100 cm (see Appendix for raw data). LY341495-treated group never 
reached the control group’s mean activity on Days 6 and 7. If the initial hypothesis were true, the 
mean activity for the treatment group should be much closer, if not higher, than the values for the 
control group on Days 6 and 7, despite the fact that the treatment group showed lower activity 
compared to the control group on all days except for Day 0 (baseline).  
No outliers could be identified from the raw data on locomotor activity due to the high 
standard deviations for both groups on each day. However, one of the rats from the treatment 
36 
 
group seemed to generally exhibit less locomotor activity compared to the others within the same 
group (Rat 1 of LY341495-treated group), but the difference was not significant enough to deem 
this subject as an outlier. Moreover, the behavioral tests were performed at the same time 
everyday for both groups, so Circadian rhythm should not have an effect on the results. The 
subjects’ test performance, dealing with learning and memory processes, in the present study 
should not have been affected by LY341495 either because the mGluII receptor antagonist 
actually improved spatial learning in mice in the Morris water maze (Higgins et al, 2004).  
The treatment group’s low level of locomotor activity might be attributable to increased 
anxiety in the rats. Previous studies have revealed that LY341495 increased anxiety-like 
behavior in mice measured by the elevated-plus maze (Linden et al, 2005). Contrary to the initial 
hypothesis, LY341495 has also been shown to have no effect on locomotor activity: in a study 
where nicotine was not involved, rats that received microinjections of the drug into their nucleus 
accumbens did not exhibit any differences in locomotor activity (Richard and Berridge, 2010).  
Another factor that may influence the results of this study is the dosage of LY341495. 
O’Neill et al. observed the locomotor activity of mice after given LY341495 – no nicotine was 
involved in this study. A range of doses were tested and results showed that hyperactivity was 
produced at the minimum effective dose of 2.5 mg/kg, while 1 mg/kg (dosage in the present 
study) did not seem to have much effect (O’Neill et al, 2003).     
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fMRI 
In order to observe the effects of LY341495 on brain activity, a new batch of rats were 
used and treated to the same drug protocol as the subjects in the behavioral study (open-field 
test).  (Note: Images of the control group were obtained from a similar nicotine study that used a 
different drug but employed the same control protocol as the present study.) It is important to 
note that there were only 2 rats in the treatment group (there was an initial n = 4) while there 
were 4 in the control group. Due to technical difficulties with the fMRI magnet, one of the rats in 
the treatment group could not be used for the study because it was in the scanner for too long 
during the repair process; and thus, the results would have been affected since the rat would have 
been too stressed. In addition, images from another subject were not as clear or well-defined as 
desired and were omitted from the analysis.    
Studies have shown that exposure to cigarette/nicotine-related cues to people dependent 
on the drug will lead to craving and subsequent increase in activity of the mesolimbic system 
(right post posterior amygdala, posterior hippocampus, VTA, and medial thalamus) (Due et al, 
2002). Increased glucose metabolism in parts of the anterior paralimbic system (ACC, posterior 
OFC, and anterior insula), DLPFC, and right superior sensorimotor cortex (Brody et al, 2002) 
are also expected. Since both the control group’s saline scan and the treatment group’s 
LY341495 scan preceded the nicotine scan in our study, the rats were expected to be in the 
craving state at this point. Thus, positive BOLD responses were predicted in the mesolimbic 
system and parts of the anterior paralimbic system as well as in the DLPFC and right superior 
sensorimotor cortex. However, as seen in Figures 8a and 9a, vital regions associated with 
nicotine craving did not show significant activation: amygdala (image 11), VTA (image 14), and 
the ACC (image 8). Brain regions such as the hippocampus, thalamus, OFC, anterior insula, and 
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DLPFC cannot be as clearly identified from the imaging scans, but there does not appear to be 
discernable activation in those regions. 
Though both pre-nicotine scans did not show much activation in majority of the brain 
regions associated with nicotine craving, the saline scan did show activation in the somatomotor 
and somatosensory areas (image 9 of Figure 8a), while the LY341495 scan displayed decreased 
activation in those regions (image 9 of Figure 9a). The decreased BOLD response seen in the 
treatment group could possibly be due to LY341495’s influence in blocking the effects of 
nicotine – which would also inhibit craving. However, this would not account for the increased 
activation of the infralimbic area seen in those treated with LY341495 (image 6 of Figure 9a) 
compared to the control (image 6 of Figure 8a).  
Similar to other drugs of abuse, nicotine is known to affect the reward pathway (Xi et al, 
2009). Thus, positive BOLD response was expected to be seen in the VTA, nucleus accumbens, 
and amygdala in the nicotine scans for both groups. In the control group’s nicotine scan (Figure 
8b), there did not seem to be activation in any of those three brain regions (images 14, 5, and 11 
respectively). However, there appeared to be slight activation in the nucleus accumbens (image 
5) and amygdala (image 11) in the treatment group’s nicotine scan (Figure 9b) but no significant 
activity in the VTA (image 14). On the other hand, a decrease in BOLD response can be seen in 
the ACC, infralimbic area, and retrosplenium when comparing the treatment group (Figure 9b) 
with the control group (Figure 8b) (images 5-10). In general, there is decreased corticolimbic 
activity in the treatment group after the administration of nicotine (Figure 9b) compared to the 
control group after receiving nicotine (Figure 8b). 
In animal studies, nicotine sensitization results in an increase in locomotor activity 
(Balfour et al, 1998). Therefore, the motor loop was thought to possibly be affected by both 
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nicotine and LY341495, and positive BOLD responses were expected in the basal ganglia: 
caudate nucleus, putamen, globus pallidus, subthalamic nucleus, and substantia nigra. However, 
the LY341495 (Figure 9a) and both nicotine scans (Figures 8b and 9b) did not show significant 
activation of the basal ganglia – though the specific brain components could not be as clearly 
identified from the imaging results.  
As mentioned earlier, there appears to be activation in the somatomotor and 
somatosensory areas (images 9 and 10 of Figure 8a) in the saline scan. Interestingly, there was 
decreased activation in those two areas after the administration of nicotine (images 9 and 10 of 
Figure 8b) but increased activity in the ACC and the infralimbic area (images 4-8 of Figures 8a 
and 8b), as well as slight increased activation in the retrosplenium (images 9 and 10 of Figures 
8a and 8b). Though the exact functions of the ACC are still debated, research has implicated the 
involvement of this brain region in conflict and error monitoring (Carter et al, 1998; Falkenstein 
et al, 2000), depression and anxiety disorders (Mayberg et al, 2000; Brody et al, 2001), and even 
pain perception (Rainville et al, 1997). In human functional imaging studies, the ACC has been 
activated during periods of anxiety – increased activation related to greater anxiety and 
decreased activation related to depressed mood (Kimbrell et al, 1999; Chua et al, 1999) –  
alertness (Sturm et al, 1999; Naito et al, 2000), arousal (Rauch et al, 1999; Stoleru et al, 1999; 
Critchley et al, 2001), focused attention (Bench et al, 1993; Keilp et al, 1997; Davis et al, 1997; 
Benedict et al, 1998; Woldorff et al, 1999), and awareness of emotional state (Lane et al, 1998). 
On the other hand, human studies have shown that the retrosplenium is responsible for episodic 
memories and navigation (Vann et al, 2009), while extinction memory of drug rewards, such as 
cocaine, has shown the involvement of the infralimbic cortex (Peters et al, 2008). 
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 When comparing the results from the treatment group (Figure 9a and 9b), slight increases 
in activity can be seen in the somatomotor and somatosensory areas (image 11) as well as in the 
infralimbic area (images 5 and 6) after the administration of nicotine. However, there was an 
overall decrease in BOLD response seen after the nicotine injection. This phenomenon could be 
attributed to LY341495’s ability to block the effects of nicotine – though this would not account 
for the increased activation of the nucleus accumbens (image 5) and amygdala (11) but inactivity 
of the VTA (image 14).   
 Aside from the already mentioned plausible explanations for the differences in brain 
activity observed between the control and treatment groups, another factor affecting the results is 
the sample size. As mentioned earlier, the images of the treatment group were from only 2 out of 
the original 4 subjects. Therefore, more rats need to be added to the treatment group in order to 
delineate statistically significant effects of LY341495. The treatment group’s scans (Figure 9) 
also show scattered BOLD responses and a significant amount of negative BOLD activity when 
compared to the scans from the control group (Figure 8). Despite performing motion artifact 
correction in Matlab, these results could have possibly been due to motion. Hence, the resulting 
images for the treatment group may not show an accurate depiction of the subjects’ brain 
activity. 
 
Conclusion 
The present study evaluated the role of glutamate in nicotine sensitization through 
behavioral tests and imaging (fMRI). The novel Group II metabotropic glutamate receptor 
antagonist LY341495 was administered to rats and their locomotor and brain activities were 
assayed. Results from the open-field test did not support the initial hypothesis that LY341495 
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would augment the effects of nicotine in sensitized rats, since LY341495-treated rats did not 
show an increase in locomotor activity compared to the controls. In addition, brain images 
(fMRI) from both the control and treatment groups were not as expected either since there was a 
lack of brain activity in regions associated with craving (pre-nicotine scans) and motor activity 
(after nicotine). No activation was seen in the reward pathway after the administration of 
nicotine in the control group, but there may have been slight activity in the amygdala and 
nucleus accumbens in the treatment group.  
To further investigate the effects of LY341495 and possibly elucidate the current results, 
the study could be repeated with a different dosage of LY341495. As mentioned earlier, O’Neill 
et al. found the minimum effective dose to produce hyperactivity to be 2.5 mg/kg. Though 
nicotine was not involved in that experiment, raising the dosage of LY341495 in the current 
study (1 mg/kg) could possibly yield different patterns in both behavioral and imaging assays. 
On the other hand, the rats may not have been in the chronic nicotine state at the time of 
testing. In the present study, the subjects received subcutaneous injections of nicotine (0.4 
mg/kg) for 5 consecutive days before receiving the treatment (LY341495) or saline. However, 
other studies that measured the effects of nicotine on locomotor activity have employed more 
days of nicotine treatment: subcutaneous nicotine injections were administered for 37 
consecutive days (0.2 or 0.4 mg/kg) by Ericson et al. (Ericson et al, 2010) and for 49 consecutive 
days (0.4 mg/kg) by Clarke and Kumar (Clarke and Kumar, 1983). To our knowledge, this is the 
first study to examine the effects of LY341495 through fMRI. This study should be repeated 
with an increased dosage of LY341495, as well as a larger sample size for imaging, in order to 
yield more accurate and statistically significant results.             
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Appendix 
 
Treatment Group (LY341495) Locomotor Activity Raw Data  
(Distance is measured in cm and ‘#2’ denotes Batch #2) 
 
 
Rat 1 Rat 2 Rat 3 Rat 4 
Rat 1 
(#2) 
Rat 2 
(#2) 
Rat 5 
(#2) 
Rat 6 
(#2) 
Baseline 12267.88 11334.56 11813.49 11275.57 12455.04 9900.54 9827.26 13224.7 
Day 1 5340.55 4025.87 3692.8 7221.23 8008.81 3018.2 5533.65 7688.7 
Day 2 4299.55 5780.79 8092.58 7703.88 8951.57 4988.47 7502.21 9218.33 
Day 3 3732.6 7203.07 5462.02 9502.06 10759.9 7374.22 7677.57 10415.68 
Day 4 6284.87 9776.57 9443.68 10922.95 12923.39 6399.29 9774.33 10535.54 
Day 5 4891.74 9356.24 9404.05 10378.85 14079.56 7928.5 10845.71 11094.13 
Day 6 7756.21 10436.41 10421.81 10853.93 12479.07 8403.2 9736.52 9968.85 
Day 7 7515.27 10633.67 11221.86 10882.31 13942.52 10002.87 12761.9 11186.18 
 
 
 
 
 
Control Group (Saline) Locomotor Activity Raw Data 
(Distance is measured in cm and ‘#2’ denotes Batch #2) 
 
 
Rat 5 Rat 6 Rat 7 Rat 8 
Rat 3 
(#2) 
Rat 4 
(#2) 
Rat 7 
(#2) 
Rat 8 
(#2) 
Baseline 10291.02 12571.88 9744.69 9035.02 10914.88 10625.22 14480.28 12950.71 
Day 1 6535.88 6699.21 5950.66 2068.45 6435.15 6262.92 7828.23 7166.76 
Day 2 7421.01 9617.35 7090.39 4334.21 8209.5 5452.42 10418.22 9141.69 
Day 3 10049.81 12624.25 8633.38 7073.36 10305.95 6993.3 11609.15 10378 
Day 4 11592.66 12633.79 10963.74 7096.06 12538.03 6291.48 13580.83 12695.31 
Day 5 13476.93 14898.27 12683.01 7446.76 11576.74 9325.52 15867.14 12676.96 
Day 6 13288.66 17187.31 12398.48 9179.41 15407.67 11403.15 16871.97 15831.2 
Day 7 13941.92 18154.34 12705.36 10825.37 15728.1 11588.48 15520.18 13723.85 
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Calculated Mean and Standard Deviations  
(Yellow-highlighted rows are calculations for treatment group while white/non-colored rows are 
for control group.) 
 
 Mean  Std Dev Mean Std Dev 
Baseline 11512.38 1195.674 11326.71 1836.993 
Day 1 5566.226 1913.747 6118.408 1735.58 
Day 2 7067.173 1830.693 7710.599 2078.177 
Day 3 7765.89 2421.717 9708.4 2018.058 
Day 4 9507.578 2233.596 10923.99 2733.047 
Day 5 9747.348 2654.996 12243.92 2778.717 
Day 6 10007 1458.851 13945.98 2847.837 
Day 7 11018.32 1894.713 14023.45 2396.451 
 
 
ANOVA: Single Factor (p < 0.05) 
 
Between Groups  
Day 1 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 44529.81 5566.226 3662429 
  Column 2 8 48947.26 6118.408 3012236 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 1219617 1 1219617 0.365447 0.555168 4.60011 
Within Groups 46722655 14 3337333 
   
       Total 47942272 15         
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Day 2 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 56537.38 7067.173 3351438 
  Column 2 8 61684.79 7710.599 4318819 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 1655989 1 1655989 0.431795 0.521766 4.60011 
Within Groups 53691796 14 3835128 
   
       Total 55347785 15         
 
 
Day 3 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 62127.12 7765.89 5864712 
  Column 2 8 77667.2 9708.4 4072556 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 15093380 1 15093380 3.037732 0.10326 4.60011 
Within Groups 69560881 14 4968634 
   
       Total 84654262 15         
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Day 4 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 76060.62 9507.578 4988950 
  Column 2 8 87391.9 10923.99 7469544 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 8024869 1 8024869 1.288257 0.275429 4.60011 
Within Groups 87209464 14 6229247 
   
       Total 95234333 15         
 
 
Day 5 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 77978.78 9747.348 7049005 
  Column 2 8 97951.33 12243.92 7721267 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 24931422 1 24931422 3.375892 0.087472 4.60011 
Within Groups 1.03E+08 14 7385136 
   
       Total 1.28E+08 15         
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Day 6 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 80056 10007 2128247 
  Column 2 8 111567.9 13945.98 8110176 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 62062293 1 62062293 12.12341 0.003665 4.60011 
Within Groups 71668955 14 5119211 
   
       Total 1.34E+08 15         
 
 
Day 7 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 88146.58 11018.32 3589939 
  Column 2 8 112187.6 14023.45 5742978 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 36123165 1 36123165 7.741023 0.014684 4.60011 
Within Groups 65330422 14 4666459 
   
       Total 1.01E+08 15         
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Within Group (LY341495) 
Day 5 vs. 6 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 77978.78 9747.348 7049005 
  Column 2 8 80056 10007 2128247 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 269677.7 1 269677.7 0.058771 0.811965 4.60011 
Within Groups 64240758 14 4588626 
   
       Total 64510436 15         
 
 
Day 5 vs. 7 
SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 8 77978.78 9747.348 7049005 
  Column 2 8 88146.58 11018.32 3589939 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 6461510 1 6461510 1.21469 0.288992 4.60011 
Within Groups 74472607 14 5319472 
   
       Total 80934117 15         
 
 
